Literature DB >> 15167601

Classical pathway complement destruction is not responsible for the loss of human erythrocytes during porcine liver perfusion.

Michael A Rees1, Andrew J Butler, Margaret C Negus, Hugh F S Davies, Peter J Friend.   

Abstract

BACKGROUND: Porcine livers perfused with human blood destroy 85% of human erythrocytes (red blood cells [RBC]) during prolonged extracorporeal perfusion, raising the possibility of a complement-mediated graft-versus-host effect.
METHODS: Isolated porcine livers were perfused with fresh human blood. Plasma samples were analyzed for complement production by reverse CH50 analysis and porcine immunoglobulin class and specificity by enzyme-linked immunosorbent assay (ELISA) and flow cytometry. Anti-CD59 and anti-decay accelerating factor (DAF) monoclonal antibody were used to investigate whether human complement regulatory proteins inhibit porcine complement.
RESULTS: After 64 hr of perfusion of porcine livers with human blood, mean complement activity in the perfusate was 95% of the starting value and increasing, whereas perfusion in the absence of a liver showed a falling complement activity of 28.7%. ELISA demonstrated porcine immunoglobulin (Ig) G and IgM in the xenoperfused human plasma. Whereas in a previous study flow cytometry demonstrated porcine antibodies specific for antigens on human T lymphocytes, in this study, anti-human RBC antibodies were not found. Xenoperfused human plasma did not lyse fresh human RBC. Human complement was consistently more efficient at lysing porcine RBC than was porcine complement at lysing human RBC, and human plasma inhibited the ability of porcine plasma to lyse human RBC, raising the possibility of cross-species complement regulation. Complement regulatory proteins on human RBC were blocked using mouse monoclonal anti-human CD59 and DAF. Blocking CD59, but not DAF, augmented lysis of human RBC by porcine complement.
CONCLUSIONS: Human CD59 inhibits porcine complement. The production of porcine complement from xenoperfused porcine livers is unlikely to result in clinically significant injury mediated through the classical pathway of complement activation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15167601     DOI: 10.1097/01.tp.0000121135.24688.a3

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  11 in total

1.  Combined yeast {beta}-glucan and antitumor monoclonal antibody therapy requires C5a-mediated neutrophil chemotaxis via regulation of decay-accelerating factor CD55.

Authors:  Bing Li; Daniel J Allendorf; Richard Hansen; Jose Marroquin; Daniel E Cramer; Claire L Harris; Jun Yan
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

Review 2.  Miniature Swine as a Clinically Relevant Model of Graft-Versus-Host Disease.

Authors:  Raimon Duran-Struuck; Christene A Huang; Katherine Orf; Roderick T Bronson; David H Sachs; Thomas R Spitzer
Journal:  Comp Med       Date:  2015-10       Impact factor: 0.982

3.  A human-specific mutation limits nonhuman primate efficacy in preclinical xenotransplantation studies.

Authors:  Joshua P Waldman; Linda G Brock; Michael A Rees
Journal:  Transplantation       Date:  2014-02-27       Impact factor: 4.939

4.  Blocking porcine sialoadhesin improves extracorporeal porcine liver xenoperfusion with human blood.

Authors:  Joshua P Waldman; Thomas Vogel; Christopher Burlak; Constantin Coussios; Javier Dominguez; Peter Friend; Michael A Rees
Journal:  Xenotransplantation       Date:  2013-07-04       Impact factor: 3.907

Review 5.  Experimental hepatocyte xenotransplantation--a comprehensive review of the literature.

Authors:  Huidong Zhou; Hong Liu; Mohamed Ezzelarab; Eva Schmelzer; Yi Wang; Jörg Gerlach; Bruno Gridelli; David K C Cooper
Journal:  Xenotransplantation       Date:  2015-05-07       Impact factor: 3.907

6.  Up to 9-day survival and control of thrombocytopenia following alpha1,3-galactosyl transferase knockout swine liver xenotransplantation in baboons.

Authors:  Karen Kim; Christian Schuetz; Nahel Elias; Gregory R Veillette; Isaac Wamala; Manish Varma; R Neal Smith; Simon C Robson; A Benedict Cosimi; David H Sachs; Martin Hertl
Journal:  Xenotransplantation       Date:  2012 Jul-Aug       Impact factor: 3.907

Review 7.  Immunobiology of liver xenotransplantation.

Authors:  Burcin Ekser; Christopher Burlak; Joshua P Waldman; Andrew J Lutz; Leela L Paris; Massimiliano Veroux; Simon C Robson; Michael A Rees; David Ayares; Bruno Gridelli; A Joseph Tector; David Kc Cooper
Journal:  Expert Rev Clin Immunol       Date:  2012-09       Impact factor: 4.473

Review 8.  Pig Liver Xenotransplantation: A Review of Progress Toward the Clinic.

Authors:  David K C Cooper; Ke-Feng Dou; Kai-Shan Tao; Zhao-Xu Yang; A Joseph Tector; Burcin Ekser
Journal:  Transplantation       Date:  2016-10       Impact factor: 4.939

Review 9.  Current status of xenotransplantation and prospects for clinical application.

Authors:  Richard N Pierson; Anthony Dorling; David Ayares; Michael A Rees; Jörg D Seebach; Jay A Fishman; Bernhard J Hering; David K C Cooper
Journal:  Xenotransplantation       Date:  2009 Sep-Oct       Impact factor: 3.907

10.  Porcine sialoadhesin: a newly identified xenogeneic innate immune receptor.

Authors:  L G Brock; P L Delputte; J P Waldman; H J Nauwynck; M A Rees
Journal:  Am J Transplant       Date:  2012-09-07       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.